Research progress on abrocitinib in the treatment of moderate and severe atopic dermatitis

Abstract

Atopic dermatitis (AD) is an inflammatory skin disease characterized by pruritus. The efficacy of traditional treatment for moderate and severe AD is not satisfactory. AD has complex and multi-factor pathophysiological mechanisms.JAK-STAT pathway plays an important role in the pathogenesis of AD. Abrocitinib is a highly selective oral inhibitor of janus kinase 1 (JAK1), which can inhibit JAK-STAT signal transduction and activation pathways, resulting in down-regulation of the expression of IL-4, IL-13 and IL-31, which all are involved in the pathogenesis of AD, and ultimately blocks the occurrence and the development of AD. Abrocitinib has shown a good efficacy, tolerability and safety in the treatment of refractory moderate to severe AD. This article reviews the pharmacological mechanisms, clinical efficacy, safety and clinical applications of abrocitinib.

Keywords

• abrocitinib
• jak1 inhibitor
• atopic dermatitis